Thus, 31 of 82 (39%) of the patients treated with 177Lu-J591 developed grade 3 or 4 thrombocytopenia in contrast to 6 of 243 (2%) of the patients treated with 177Lu-PSMA-617 and 177Lu-PSMA I&T (p < 0.001, χ2 test with one degree of freedom) [32, 33, 37, 38, 41]. Here, FOLH1 is linked to Thrombocytopenia.